Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- 26 Suspected Violations in Detailing Activities Reported in FY2021: MHLW
August 12, 2022
- Nippon Shinyaku’s MonoVer Iron Deficiency Drug Skips August Listing
August 12, 2022
- Katsunobu Kato Makes Yet Another Comeback as Health Minister
August 10, 2022
- Chuikyo OKs Lagevrio, Voxzogo, Enjaymo, and More for August Listing, BioMarin Med with Biggest Peak Sales Outlook
August 10, 2022
- Rybelsus Faces 2.5-2.6% Price Cut in November under CEA Scheme; No Change for Cabometyx
August 10, 2022
- Deliberations Underway for Transfer of Some MHLW Functions to Boost Pandemic Responses: Vice Health Minister
August 10, 2022
- Japan to Begin BA.1-Based Omicron Booster Program as Early as October
August 9, 2022
- MHLW to Set Up Panel to Promote Biosimilars as Early as Next Year: Official
August 9, 2022
- E Keppra Now Eligible for Health Coverage for Status Epilepticus
August 8, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
August 8, 2022
- LDP Project Team to Make Proposals for Japan-Moderna Deal
August 8, 2022
- MHLW Panel Members Support Silgard 9 HPV Vaccination for Ages 9-14
August 5, 2022
- Chuikyo OKs Insurance Coverage for CureApp’s Hypertension Therapeutic App
August 5, 2022
- MHLW Panel OKs Onoact for Pediatric Tachyarrhythmia and More Drugs
August 5, 2022
- Evaluate Shionogi COVID Pill Based on Omicron Symptoms: Komeito Lawmakers
August 5, 2022
- Janssen’s CAR-T Therapy, Kymriah Label Expansion Now in Line for Approval
August 4, 2022
- Chuikyo Will Consider Any Proposals of New Panel on Drug Pricing: Pharma Management Director
August 3, 2022
- Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
August 2, 2022
- Supply Chain Clause of Economic Security Law Now in Effect
August 2, 2022
- MHLW Presents Plan for Monkeypox Vaccinations with KM Biologics’ Jab
August 2, 2022
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…